Exicure Lays Off Two-Third Employees, Ceases R&D Activities
Exicure Inc (NASDAQ:XCUR) announced restructuring plans and aligned resources to continue exploring strategic alternatives. The company will cut its workforce by…
‘Biogen Agrees to Pay $900 Million Over Alleged Improper Physician Payments’ -WSJ
https://www.wsj.com/articles/biogen-agrees-to-pay-900-million-over-alleged-improper-physician-payments-11664231855?mod=latest_headlines
If You Invested $1,000 In BioNano (BNGO) Stock At Its COVID-19 Pandemic Low, Here’s How Much You’d Have Now
Investors who bought stocks during the COVID-19 market crash in 2020 have generally experienced some big gains in the past two years. But there is no question some big-name stocks performed better than others since the pandemic bottom.
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval For Phase 1/1b Clinical Trial Of Mupadolimab In China
BURLINGAME, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the IND application to initiate
This Analyst Says Artivion’s Sell Off Seems Overdone After Trial Halt
On Friday, Artivion Inc (NYSE:AORT) stopped the PROACT Xa clinical trial after the Data Safety Monitoring Board (DSMB) indicated that…
Inventiva’s NASH Pact In China Represents ‘Financially Prudent Pathway,’ Says This Analyst
Last week, Inventiva (NASDAQ:IVA) announced a licensing and collaboration agreement with Sino Biopharm’s subsidiary Chia Tai-Tianqing Pharmaceutical Group (CTTQ) to…
Adial Pharma Touts Positive Preclinical Data From Chronic Pain Candidate
Adial Pharmaceuticals Inc’s (NASDAQ:ADIL) subsidiary, Purnovate Inc, achieved positive in vivo data for PNV-5030 as a potential treatment for chronic pain.…
Lipocine To Focus On Central Nervous System Conditions; Explores Partnerships For Non-Core Assets
Lipocine Inc (NASDAQ:LPCN) announced its plans to focus on treating Central Nervous System (CNS) disorders. The company’s priority is to advance…
Arcutis Shares Gain On Positive Phase 3 Data On Roflumilast Foam In Scalp, Body Psoriasis
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) announced topline results from the ARRECTOR Pivotal Phase 3 trial of roflumilast foam 0.3% for treating adults…
Atea Pharma’s Investigational Dengue Treatment Fast Tracked In US
The FDA has granted Fast Track Designation for Atea Pharmaceuticals Inc’s (NASDAQ:AVIR) AT-752 for treating dengue virus infection. AT-752, a novel, orally…